Anhui BBCA Pharmaceuticals Co., Ltd. Is located in Chinese beautiful province, Anhui, which has more than 2200 years history. Anhui province is an inland province near river and sea, in the east of China, next to the Yangtze River Delta Economic Area centering in Shanghai. It has beautiful natural views and profound cultural details, with a total area of 139.6 thousand sq. Km, and a total population of 62 million. It has discernible seasons and mild climate. The world natural and cultural heritage Huang Mountain is just located in Anhui.

Anhui BBCA Pharmaceutical Co., Ltd. Is the mainstay subsidiary of BBCA Group. BBCA Pharmaceuticals is located in the capital of Anhui province, Hefei. It is the largest pharmaceutical enterprise in Anhui. It is the high technology enterprise determined by The Ministry of Science and Technology and Chinese Academy of Sciences, as well as the national GMP certified enterprise and the People-trusted drug brand awarded by Chinese government in 2006. It was listed in Sep 4, 2000 in Shenzhen stock Exchange after obtaining the approval of China Securities Regulatory Commission. Up to the end of 2007, the company had more than 4500 employees and a total capital of about 1.1 billion RMB.

BBCA Pharmaceuticals is constituted of three systems which are pharmaceutical R& D, production, and sale. It has five pharmaceutical plants and 42 GMP certified production line, mainly involving R& D, production and sale of biological pharmacy, chemical pharmacy, and traditional Chinese medicine and possessing six classes of products including antipyretic-analgesic drug, antibiotic, anti-tumor drug, preparation of traditional Chinese medicine, cardiovascular drug, and nervous system drug. BBCA Pharmaceuticals can produce 11 formulations including large-volume injection, small-volume injection, powder injection, capsules, powders, tablets, granules, films, eye drops, patches, etc, 395 varieties, as well as many kinds of material drugs. There are more than 40 varieties of national new drugs being researched and developed, some of which have come into the market. BBCA Pharmaceuticals has many varieties of the first and second national new medicine and has the independent intellectual property of the products and various production technologies. While pursuing scale and series production, the company carried out the strategy of omnidirectional market cultivation and development, based on Anhui and influencing the world. It has set up the sales offices in more than 30 provinces, municipalities and autonomous regions all over the country. The sales networks for some products have been established in Southeast Asia, Africa, and South America.